Colorectal Cancer Drug Discoveries: what the future holds

Table of Contents

• EXECUTIVE SUMMARY
• THE FACTS
  • WHAT IS CRC AND HOW DOES IT AFFECT PATIENTS?
    • Risk Factors
    • Stages of the Disease
  • PATIENT STATISTICS
    • Incidence, Mortality and Prevalence
    • Survival Statistics
• PATIENT MODEL
  • The addressable CRC market will increase by 2 per cent by 2015
  • DRUG GROWTH DRIVERS
  • DRUG GROWTH RISKS/DAMPENERS
• THE CRC MARKET
  • GLOBAL CRC SALES SPLIT
    • US Market
    • European Market
    • Japanese Market
• THE PLAYERS
  • Players and Products in 2008
  • Players and Products in 2015
• CURRENT TREATMENTS
  • CHEMOTHERAPY
    • Current Products' Patent Exposure
  • TARGETED THERAPY
    • Targeting the VEGF Pathway
    • Targeting the EGF Pathway
    • Current Products' Patent Exposure
• ANALYSIS OF LEADING BRANDS
  • CHEMOTHERAPY
    • Cytotoxic Agents
    • Antimetabolites
  • TARGETED THERAPY
  • GLOBAL SALES FORECASTS OF LEADING BRANDS 2008A - 2015E
    • Model Assumptions
• RESEARCH & DEVELOPMENT OF CRC DRUGS
  • ANALYSIS OF PHASE III DRUGS
    • Targeted Therapy
    • Vaccines
  • GLOBAL SALES FORECASTS OF PHASE III CRC DRUGS 2008A - 2015E
    • Model Assumptions
  • ANALYSIS OF PHASE II DRUGS
    • Targeted Therapy
    • Chemotherapy
    • Vaccines
    • Other Drugs Of Interest
• COMPETITOR RATIO ANALYSIS
  • Competitor Ratio Analysis Criteria
  • COMPETITOR RATIO ANALYSIS - PRODUCTS
  • COMPETITOR RATIO ANALYSIS - COMPANIES
  • WINNERS AND LOSERS
  • Winners
  • Losers
• DISCONTINUATION OF DRUGS
• APPENDIX 1: PATIENT MODEL
• APPENDIX 2: GLOBAL CRC DRUG SALES
• APPENDIX 3: PHASE TRANSITION PROBABILITY
• GLOSSARY
• BIBLIOGRAPHY
• ACRONYMNS

INDEX OF TABLES

• Classification of CRC
• European Prevalence of CRC
• Japanese Prevalence of CRC
• Survival of CRC Patients Relative to Stage at Diagnosis
• Summary of CRC Patient Population Forecasts in Top Seven Countries (2008-2015)
• Comparison of Leading CRC Agents
• Patent Exposure of Leading Brands
• Ranking of Specialist Oncologist Sales Forces
• Proposed Filings of New Indications for Avastin
• Global CRC Sales Forecasts of Leading Brands 2008A-2015E (US$ millions)
• Products in Clinical Development for the Treatment of CRC
• New Drugs in Phase III Development to Treat CRC
• Sales Forecasts of Phase III Developmental CRC Drugs (US$ millions)
• New Drugs in Phase II Development to Treat CRC
• Studies in Metastatic CRC with EGFr-Targeting Monoclonal Antibodies in Irinotecan-Refractory Patients
• Safety Profiles of Leading Anti-EGFr Products and Nimotuzumab
• Key CRC Drugs Analysed
• Summary of Key Companies and Drugs in the CRC Market by 2015
• CRC Drugs Discontinued During Development
• Summary of US CRC Patient Population Forecasts
• Summary of Europe (Top Five) CRC Patient Population Forecasts
• Summary of Japan CRC Patient Population Forecasts
• Global CRC Drugs Sales 2008A-2015E
• Probability of Launch

INDEX OF CHARTS

• Schematic of the Lower Gastrointestinal Tract
• Incidence of CRC in the US and Western Europe
• Incidence of CRC in Men and Women in the US
• US New Cancer Deaths Estimates (2008)*
• CRC Death Rates for Men and Women in the US
• Global CRC Market by Therapy Class (2008A)
• Global CRC Market by Therapy Class (2015E)
• Global CRC Market by Region (2008A)
• CRC US Drugs Sales Split (2008A)
• CRC European Drugs Sales Split (2008A)
• Market Share of Major CRC Players by Sales (2008A)
• Global Market Share of CRC Players by Sales (2015E)
• Agents Targeting the VEGF Pathway
• Overexpression of EGFr Correlates with Increased Metastasis, Decreased Survival and a Poor Prognosis
• Inhibition of EGFr Prevents Tumour Growth and Dissemination and Induces Cell Death (apoptosis)
• Camptosar CRC Sales (2008A-2015E)
• Eloxatin CRC Sales (2008A-2015E)
• Xeloda CRC Sales (2008E-2015E)
• Avastin EU Patient Share
• Avastin CRC Sales (2008E-2015E)
• Erbitux CRC Sales (2008A-2015E)
• Schematic of EGFr Inhibition in Tumourgenesis
• Vectibix CRC Sales (2008A-2015E)
• 2008 Survey: Medicines in Development for Cancer
• Aflibercept CRC Sales (2012E-2015E)
• Litx Therapy CRC Sales (2011E-2015E)
• Recentin Mechanism Of Action
• Efficacy and Pharmacokinetic Profile of Recentin (AZD2171) Compared to Avastin
• Recentin Development Timelines
• Recentin CRC sales (2012E-2015E)
• Sutent CRC Sales (2013E-2015E)
• Study 8701 - Overall Survival In Stage II Colon Cancer Patients
• Colon Cancer Stage at Diagnosis (2008)
• Colon Cancer CRC Stage at Diagnosis (2012)
• OncoVAX CRC Sales (2014E-2015E)
• Arenegyr Structure and Activity
• NGR006 Phase II Trial in CRC
• MolMed Product Pipeline
• TroVax Method of Action